Lincoln Capital Corp’s Immunic IMUX Stock Holding History

Lincoln Capital Corp’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,040	Closed	-$22.6K	–	103
2026 Q1	$22.6K	Buy	+2,040	New	+$18.3K	0.01%	99

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Lincoln Capital Corp's IMUX Position: Q2 2026 in Review

Lincoln Capital Corp sold out of Immunic (IMUX) in Q2 2026, closing a stake of 2,040 shares — an estimated $22.6K sold.

Lincoln Capital Corp first reported a position in IMUX in Q1 2026 and held it in 1 quarter. The position peaked at $22.6K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Lincoln Capital Corp reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Lincoln Capital Corp sold 2,040 Immunic shares in Q2 2026, an estimated $22.6K.
Lincoln Capital Corp first reported a position in Immunic in Q1 2026 and held it in 1 quarter.
Lincoln Capital Corp's Immunic position peaked at $22.6K in Q1 2026.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Lincoln Capital Corp's 13F filing for Q2 2026, filed 16 Jul 2026.